Nurix Therapeutics (NRIX) Receivables - Net (2020 - 2025)

Nurix Therapeutics (NRIX) has reported Receivables - Net for 6 consecutive years, with $5.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Net changed 0.0% year-over-year to $5.0 million; the TTM figure through Nov 2025 stood at $5.0 million (changed 0.0% YoY), while the FY2025 annual figure was $5.0 million, changed 0.0% from the prior year.
• Receivables - Net retreated to $5.0 million in Q4 2025 per NRIX's latest filing, from $19.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $19.0 million in Q2 2025 and bottomed at $1.0 million in Q4 2022.
• Historically, Receivables - Net has averaged $4.9 million across 5 years, with a median of $5.0 million in 2021.
• Annual changes were most pronounced in 2022 — Receivables - Net slumped 83.33% — and 2023, when it soared 300.0%.
• Nurix Therapeutics' Receivables - Net stood at $6.0 million in 2021, then plunged by 83.33% to $1.0 million in 2022, then jumped by 300.0% to $4.0 million in 2023, then climbed by 25.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
• Business Quant data shows NRIX's Receivables - Net at $5.0 million in Q4 2025, $19.0 million in Q2 2025, and $7.0 million in Q1 2025.